Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry CV2 2DX, UK.
Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, P.O. Box 34110, Doha, Qatar.
Trends Endocrinol Metab. 2019 Jul;30(7):419-431. doi: 10.1016/j.tem.2019.04.011.
Hexokinase-2 (HK2) was recently found to produce increased metabolic flux through glycolysis in hyperglycemia without concurrent transcriptional or other functional regulation. Rather, stabilization to proteolysis by increased glucose substrate binding produced unscheduled increased glucose metabolism in response to high cytosolic glucose concentration. This produces abnormal increases in glycolytic intermediates or glycolytic overload, driving cell dysfunction and vulnerability to the damaging effects of hyperglycemia in diabetes, explaining tissue-specific pathogenesis. Glycolytic overload is also activated in ischemia-reperfusion injury and cell senescence. A further key feature is HK2 displacement from mitochondria by increased glucose-6-phosphate concentration, inducing mitochondrial dysfunction and oxidative stress. This pathogenic mechanism suggested new targets for therapeutics development that gave promising outcomes in initial clinical evaluation.
己糖激酶-2(HK2)最近被发现可在高血糖情况下增加糖酵解的代谢通量,而无需同时进行转录或其他功能调节。相反,通过增加葡萄糖底物结合来稳定蛋白酶解,可在高细胞溶质葡萄糖浓度下产生无计划的葡萄糖代谢增加。这会导致糖酵解中间产物的异常增加或糖酵解过载,从而导致细胞功能障碍和对糖尿病高血糖的破坏性影响的易感性,解释了组织特异性发病机制。糖酵解过载在缺血再灌注损伤和细胞衰老中也被激活。另一个关键特征是葡萄糖-6-磷酸浓度增加导致 HK2 从线粒体位移,从而诱导线粒体功能障碍和氧化应激。这种致病机制为治疗药物的开发提供了新的靶点,在初步临床评估中取得了有希望的结果。